To evaluate the potential efficacy and safety of primary intravitreal ranibizumab in patients with symptomatic retinal arterial macroaneurysm (RAM).
This prospective study comprised 5 eyes with RAM treated with intravitreal ranibizumab. At baseline, all patients underwent best-corrected visual acuity (BCVA) measurement, ophthalmic examination including slit-lamp biomicroscopy, and central foveal thickness (CFT) measurement using optical coherence tomography. Fluorescein angiography was also performed to confirm diagnosis. Patients were examined at 1 month after injection and monthly thereafter. Main outcome measures included changes in BCVA and CFT. Safety was assessed by ophthalmic examination and report of systemic adverse effects.
There was a statistically significant difference in BCVA (p<0.001) and CFT (p<0.001) before and after the ranibizumab injection at the end of the follow-up of 13.4 ± 3.2 months. One injection appeared to be sufficient for the resolution of macular edema and absorption of hemorrhages. No observable ocular or systemic side effects were found. One patient developed foveal atrophy.
Intravitreal ranibizumab seems to be effective and safe for the treatment of symptomatic RAM.
Eur J Ophthalmol 2017; 27(2): 215 - 219
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsIrini Chatziralli, Aggeliki Maniatea, Kyriakoula Koubouni, Efstratios Parikakis, Panagiotis Mitropoulos
- • Accepted on 03/08/2016
- • Available online on 07/09/2016
- • Published in print on 10/03/2017
This article is available as full text PDF.
- Chatziralli, Irini [PubMed] [Google Scholar] , * Corresponding Author (email@example.com)
- Maniatea, Aggeliki [PubMed] [Google Scholar]
- Koubouni, Kyriakoula [PubMed] [Google Scholar]
- Parikakis, Efstratios [PubMed] [Google Scholar]
- Mitropoulos, Panagiotis [PubMed] [Google Scholar]
2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens - Greece